China’s NDRC Approves Health Care Steps On Hospitals, Foreign Doctors Among Others
This article was originally published in PharmAsia News
China’s National Development and Reform Commission decentralized or canceled five health care-related administrative approvals among 50 measures across a wide variety of policy areas, including sole proprietorship hospital establishments by Hong Kong, Macau and Taiwan investors.
You may also be interested in...
Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.